You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國家醫保局發布常規準入藥品名單新增148個品種
阿思達克 08-21 08:03

國家醫保局正式發布《國家基本醫療保險、工傷保險和生育保險藥品目錄》,公布了國家基本醫療保險、工傷保險和生育保險常規準入部分的藥品名單。

國家醫療保障局醫藥管理司司長熊先軍表示,此次目錄調整常規准入部份共新增了148個品種,其中西藥47個、中成藥101個。

新增藥品覆蓋了要優先考慮的國家基本藥物、癌症及罕見病等重大疾病治療用藥、慢性病用藥、兒童用藥等,其中通過常規准入新增重大疾病治療用藥5個,糖尿病等慢性病用藥36個,兒童用藥38個,絕大部分國家基本藥物通過常規准入或被納入擬談判藥品名單,並將74個基本藥物由乙類調整為甲類。

此外,對於臨床價值高但價格昂貴或對基金影響較大的專利獨家藥品,根據專家評審和投票遴選結果,初步確定將128個藥品納入擬談判准入範圍,包括109個西藥和19個中成藥。這些藥品的治療領域主要涉及癌症、罕見病等重大疾病、丙肝、乙肝以及高血壓、糖尿病等慢性病等。下一步待徵求企業談判意向後,確定最終談判藥品名單。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account